Halozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 20,000 Shares

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 20,000 shares of the stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $107.43, for a total value of $2,148,600.00. Following the sale, the chief executive officer owned 767,780 shares in the company, valued at approximately $82,482,605.40. This represents a 2.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Torley also recently made the following trade(s):

• On Friday, September 11th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $107.24, for a total value of $2,144,800.00.
• On Tuesday, August 18th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $104.18, for a total value of $2,083,600.00.
• On Wednesday, July 8th, Helen Torley sold 1,923 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $79.77, for a total value of $153,397.71.

Halozyme Therapeutics Trading Up 0.2%

Halozyme Therapeutics stock opened at $107.20 on Friday. Halozyme Therapeutics, Inc. has a one year low of $61.22 and a one year high of $111.15. The business’s fifty day moving average is $93.73 and its 200 day moving average is $76.97. The stock has a market capitalization of $12.17 billion, a PE ratio of 32.00, a price-to-earnings-growth ratio of 0.41 and a beta of 0.88. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. The business had revenue of $481.00 million during the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.Halozyme Therapeutics’s revenue was up 47.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 8.25 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Wells Fargo & Company raised their target price on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. HC Wainwright reiterated a “buy” rating and set a $115.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday, September 2nd. Wall Street Zen raised Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. UBS Group restated a “buy” rating and issued a $90.00 price target on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Finally, Citizens Jmp lifted their price objective on Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a report on Friday, August 7th. Nine investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $91.20.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Measured Wealth Private Client Group LLC increased its holdings in Halozyme Therapeutics by 51.5% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 124 shares during the last quarter. Larson Financial Group LLC grew its position in shares of Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 343 shares during the period. MidFirst Bank bought a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at $27,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Halozyme Therapeutics in the 2nd quarter worth $28,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Halozyme Therapeutics in the 2nd quarter worth $30,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company’s primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.

Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements.